Finding ways to overcome resistance to ibrutinib in mantle cell lymphoma
Official title: Overcoming ibrutinib resistance in mantle cell lymphoma
Funded at Beckman Research Institute/city of Hope · NIH-11017849 · Data updated 2026-11-12
This study is looking at why some people with mantle cell lymphoma stop responding to the drug ibrutinib, focusing on a protein called NFκB, to find ways to help those who aren't getting better with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | February 1, 2021 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $450,309 |
| NIH project number | 5R01CA244576-05 |
| Project ID | NIH-11017849 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mantle cell lymphoma who have experienced resistance to ibrutinib treatment.
✕Less likely to help
Patients with mantle cell lymphoma who have not been treated with ibrutinib or those with other types of blood cancers may not benefit from this research.
What this research studies
This research investigates how some patients with mantle cell lymphoma develop resistance to the drug ibrutinib, which is used to treat certain types of blood cancers. The study focuses on understanding the role of a protein called NFκB and its signaling pathways in this resistance. By examining tumor samples and the surrounding microenvironment, researchers aim to identify mechanisms that contribute to treatment failure. The goal is to develop strategies to improve outcomes for patients who do not respond to current therapies.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with mantle cell lymphoma who are resistant to ibrutinib.
How similar studies have gone: Previous research has shown that targeting NFκB pathways can be effective in other cancers, suggesting potential for success in this area as well.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Danilov, Alexey V. — Beckman Research Institute/city of Hope
- Study coordinator: Danilov, Alexey V.
Related research
Other NIH-funded projects on the same topics.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
ERBB signaling and ibrutinib resistance in mantle cell lymphoma
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.